Polycystic Ovarian Syndrome - Pipeline Review, H2 2011

Polycystic Ovarian Syndrome - Pipeline Review, H2 2011


September 28, 2011
51 Pages - SKU: GMD6577902
License type:
Online Download      US $500.00
Global Site License      US $1,500.00
Polycystic Ovarian Syndrome - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2011', provides an overview of the Polycystic Ovarian Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Ovarian Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome. 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Polycystic Ovarian Syndrome.
  • A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Polycystic Ovarian Syndrome therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More Obstetrics/Gynecology reports by Global Markets Direct

Endometrial Cancer - Pipeline Review, H1 2014 by Global Markets Direct
Endometrial Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2014’, provides an overview of the Endometrial Cancer’s therapeutic pipeline.This ...
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014 by Global Markets Direct
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014’, provides an overview of the ...
Vulvovaginal Candidiasis - Pipeline Review, H1 2014 by Global Markets Direct
Vulvovaginal Candidiasis - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Vulvovaginal Candidiasis - Pipeline Review, H1 2014’, provides an overview of the Vulvovaginal Candidiasis’s therapeutic pipeline.This ...
Epithelial Ovarian Cancer - Pipeline Review, H1 2014 by Global Markets Direct
Epithelial Ovarian Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Epithelial Ovarian Cancer - Pipeline Review, H1 2014’, provides an overview of the Epithelial Ovarian ...
See all reports like this >>